


available at [www.sciencedirect.com](http://www.sciencedirect.com)[www.elsevier.com/locate/yexcr](http://www.elsevier.com/locate/yexcr)

## Review Article

# Notch signaling in intestinal homeostasis across species: the cases of *Drosophila*, Zebrafish and the mouse

Silvia Fre<sup>a</sup>, Allison Bardin<sup>b</sup>, Sylvie Robine<sup>a,\*</sup>, Daniel Louvard<sup>a</sup>

<sup>a</sup> Morphogenesis and Intracellular Signaling, Institut Curie, UMR 144 CNRS, Paris, France

<sup>b</sup> Stem Cells and Tissue Homeostasis, Institut Curie, UMR3215 CNRS, U934 Inserm, Paris, France

### ARTICLE INFORMATION

#### Article Chronology:

Received 13 May 2011

Revised version received 21 June 2011

Accepted 21 June 2011

#### Keywords:

Notch signaling

Intestine

Stem cells

Tumorigenesis

*Drosophila*

Mouse

### ABSTRACT

Notch signaling has been recently shown to have a fundamental role in stem cell maintenance and control of proper homeostasis in the intestine of different species. Here, we briefly review the current literature on Notch signals in the intestine of *Drosophila*, Zebrafish and the mouse, and try to highlight conserved and divergent Notch functions across species. Notch signals show a remarkably conserved role in skewing cell fate choices in intestinal lineages throughout evolution. Genetic analysis demonstrates that loss of Notch signaling invariably leads to increased numbers of secretory cells and loss of enterocytes, while gain of Notch function will completely block secretory cell differentiation. Finally, we discuss the potential contribution of Notch signaling to the initiation of colorectal cancer by controlling the maintenance of the undifferentiated state of intestinal neoplastic cells and speculate on the therapeutic consequences of affecting cancer stem cells.

© 2011 Published by Elsevier Inc.

### Contents

Introduction . . . . .	0
Notch signals in the fly . . . . .	0
Notch signals in the Zebrafish intestine . . . . .	0
Notch signals in the mouse intestine . . . . .	0
Notch signals in intestinal tumors . . . . .	0
Conclusive remarks . . . . .	0
References . . . . .	0

### Introduction

Notch signaling plays a fundamental and evolutionarily conserved role in metazoan development. Extensive molecular and genetic

analyses, based primarily on invertebrate studies, established that the general developmental role of Notch signals is to link cell fate choices of one cell to those of a cellular neighbor. Notch signals are highly pleiotropic, dictating cellular fates in a way that depends on

\* Corresponding author.

E-mail address: [sylvie.robine@curie.fr](mailto:sylvie.robine@curie.fr) (S. Robine).

cellular context. Thus, Notch activity can influence differentiation, proliferation or apoptotic events in a wide range of tissues depending on the presence of other cellular elements and the ability of Notch signals to integrate with other signaling pathways [1,2]. The fundamental nature of Notch signals in metazoan development is reflected by the fact that aberrant Notch signaling invariably leads to mutant phenotypes in every system examined and in humans it underlies a growing spectrum of pathologies [3–7], including cancer [8–13].

In this short review, we focus on the role of Notch signals in the maintenance of proper homeostasis in the intestine of different species: *Drosophila*, Zebrafish and the mouse.

## Notch signals in the fly

The adult intestine of *Drosophila melanogaster* has been recently exploited as a simple model system to study intestinal biology (see accompanying review in this issue for more details). Though lacking crypt-villus structures, the fly intestinal epithelial cells use a brush border luminal surface to perform absorptive functions. Like its mammalian counterpart, the fly intestine hosts a large number of multipotent stem cells, which self-renew and continuously replenish the epithelium. Stem cells have been identified in various regions of the fly digestive tract, but those of the posterior midgut are, to date, the best characterized and will be further discussed here as “intestinal stem cells”. In contrast to vertebrates, though, fly intestinal stem cells appear to produce only two types of terminally differentiated cells, enteroendocrine cells and enterocytes [14,15]. The lumen of the fly intestine is lined by a chitinous peritrophic membrane, acting as a barrier that may perform some of the physiological activities of goblet and paneth cells. Enteroendocrine cells are also heterogeneous in their expression of peptide hormones and therefore may have some degree of specialization [14,15]. The niche-like function of paneth cells may be filled by the enterocytes and surrounding muscles cell, both of which secrete mitogens important to control stem cell proliferation ([16–19]; see also review in this issue). Unlike the mouse intestine, the *Drosophila* midgut does not contain a transit-amplifying population of progenitors, but rather the stem cells give rise to intermediate progenitor cells, enteroblasts, that will terminally differentiate into one of the two differentiated cell types, the secretory or absorptive cells without further divisions.


Compared to its mammalian counterpart, the *Drosophila* midgut represents a greatly simplified model system in terms of cell types and lineages with which to investigate how Notch signaling mediates cell fate decisions and cell fate specification. However, morphological and histological markers of specific cell types are less well defined in the fly and the identification of different cells relies on a combination of epitope (including the Notch ligand Delta) and enhancer trap markers, lineage tracing techniques, and mitotic cell state. Enteroendocrine cells are post-mitotic secretory cells; they express the transcription factor Prospero, and often produce peptide hormones such as tachykinin and allatostatin. The enterocytes express the transcription factor Pdm1 and undergo endoreplication of their DNA (a common feature of many post-mitotic fly cells); consequently, these cells become very large and present a characteristic big nucleus, they have an actin-rich apical brush border that contributes to the majority of the luminal surface.

The Notch signaling pathway controls cell fate decisions of the intestinal stem cell and its daughter cells. Both the Notch ligand Delta and the Notch receptor are expressed in the stem cells and are present in both daughter cells immediately after stem cell division. Delta expression is then lost in the differentiating daughter cell, while Notch expression is maintained in the EB and young differentiating enterocytes, but not in mature enterocytes or enteroendocrine cells [15,20]. Delta sends a signal from one daughter cell to activate the Notch transcriptional response in its adjacent sister cell, thereby promoting its commitment to differentiation, while the signal sending cell does not activate Notch and retains stem cell identity [14,15,20]. The exact mechanisms allowing activation of Notch in one cell and preventing activation in the other cell are not fully understood. Transcriptional repression of Notch target genes is mediated by the Hairless/Suppressor of Hairless repression complex and by chromatin modifications via the histone ubiquitin protease Scrawny, which helps maintaining stem cells by preventing Notch target gene activation. Loss of either *Hairless* or *Scrawny* leads to a loss of Delta positive stem cells [21,22]. Whether other factors impact on the Notch switch is unclear, though the negative regulator Numb does not influence this decision [21].

Genetic analysis of loss and gain of Notch signaling demonstrates the important role of this pathway in cell fate specification in the intestine. The clonal loss of Notch in adult stem cells results in the aberrant production of cell types. While wild-type stem cells self-renew, keeping their number relatively constant, and produce new terminally differentiated enterocytes and enteroendocrine cells, Notch mutant mitotic clones contain many more stem cell-like cells (Delta+, mitotic cells), many more enteroendocrine cells (Prospero+, allatostatin+), and lack enterocytes (large polyploid, Pdm1+ cells) [14,15] (Fig. 1). The reverse is also true: expression of a constitutively active form of Notch in single stem cells drives their terminal differentiation into large, polyploid enterocytes [14] (Fig. 1). It should be noted, however, that distinction of the cell types in mutant contexts relies on the expression of relatively few known markers, leaving the possibility open that these cells may differ from their wild-type counterparts.

In the fly intestine, the only identified Notch target genes to date are the Hes orthologs, the Enhancer of split-Complex [E(spl)-C] [18,21]. Loss of the *E(spl)-C* leads to an increase in the number of Delta+ stem-cell-like cells and to a loss of enteroendocrine cells, without affecting the enterocytes [21]. Interestingly, the number of Prospero+ enteroendocrine cells can be restored if Notch signaling is impaired in *E(spl)-C* mutants, suggesting that the *E(spl)-C* genes are not directly required for enteroendocrine fate and that other Notch targets may inhibit this fate. In addition, the presence of enterocytes in the *E(spl)-C* mutants indicates that yet unidentified target genes are required for enterocyte specification. It has also been suggested that the level of Notch signaling may have an impact on cell fate specification [20]; it will therefore be important to identify Notch target genes in the fly intestine and to understand how they may differentially respond to Notch levels.

The E(spl) family of proteins has been shown in many contexts to inhibit the activity of basic helix-loop-helix (bHLH) transcription factors. Of note, during lateral inhibition in the fly, the bHLH proteins are part of a regulatory loop acting both upstream and downstream of Notch signaling: they can directly promote Delta expression but they are repressed downstream of Notch signaling by E(spl) proteins [23,24]. In the fly intestine, loss of the bHLH



**Fig. 1 – Conserved role of Notch signaling in controlling cell fate specification in the intestine. Over expression of activated Notch (green in A) in *Drosophila* stem cells drives their differentiation into enterocytes (large, polyploid cells, an example of which is indicated by a white arrow). The loss of Notch signaling (illustrated in B in *Delta* mutant tissue outlined in white) causes excess enteroendocrine cells (green Prospero+, a subset of which are also Allatostatin+ in red) and a loss of enterocytes (A.B., Carolina Perdigoto and François Schweisguth, unpublished data). Similarly, ectopic expression of active Notch in the intestinal epithelium (C) completely blocks secretory cell differentiation as shown by the absence of PAS + Goblet cells. On the contrary, loss of Notch signaling achieved by deletion of RBPJ (D) leads to a dramatic increase of PAS + secretory cells (labeled in purple in D).**

174 protein *Daughterless* in stem cells results in their terminal  
 175 differentiation as enterocytes suggesting that *Daughterless* is  
 176 required to maintain intestinal stem cell identity. Additional  
 177 bHLH factors are important for enteroendocrine differentiation  
 178 as cells lacking the *achaete-scute-complex* fail to produce enter-  
 179 oendocrine cells. Conversely, the overexpression of *scute* is  
 180 sufficient to produce Prospero + enteroendocrine cells, suggesting  
 181 that this family of bHLH genes is specifically important for  
 182 enteroendocrine fate acquisition [21]. The role of bHLH factors  
 183 for both stem cell maintenance (*Daughterless*) and secretory cell  
 184 differentiation (*achaete-scute-complex*) may be similar to the  
 185 mouse where the bHLH homologue *Ascl2* (*achaete-scute-like 2*)  
 186 is required for intestinal stem cell identity [25], while the bHLH  
 187 genes *Math1* and *Ngn3* play specific roles in secretory lineage  
 188 specification [26–28] (see below). The shared features of Notch  
 189 signaling in the fly and mouse intestine suggest that the use of the  
 190 fly as a genetic model system to understand Notch pathway  
 191 modulation will be fruitful (Fig. 2).


### 193 Notch signals in the Zebrafish intestine

194 As in the fly and mouse systems, Notch signals appear to be required  
 195 in the developing Zebrafish intestine. Loss of Notch signaling in  
 196 *mindbomb* homozygous fish leads to increased numbers of secretory  
 197 cells and a loss of enterocytes, indicating a strikingly conserved role  
 198 in cell fate specification throughout evolution [29]. Conversely, *brom*

*bones* mutants, which exhibit increased expression of Notch target  
 genes, show defects in goblet cell specification and an increase in  
 proliferative cells; the identity of the proliferating cells is unclear  
 though, due to lack of appropriate markers [30]. The *Hes1* homologs  
*her6* and *her9* appear to be expressed in response to Notch signaling  
 in the fish intestine [30]. The further development and use of  
 Zebrafish as a model system to study intestinal biology will  
 undoubtedly provide valuable insights.

### Notch signals in the mouse intestine

The first demonstration of a direct role for Notch signals in  
 controlling the segregation of each mature intestinal lineage from  
 undifferentiated progenitor cells, as well as in the maintenance of  
 the proliferating intestinal cell pool, came from the analysis of  
 transgenic mice carrying either a loss of function [31] or a gain of  
 function [32] Notch pathway mutation. When Notch signaling is  
 inhibited by deletion of the core transcriptional effector of Notch  
 signaling *RBPJ $\kappa$*  [33], all crypt cells cease to proliferate and  
 differentiate into secretory cells (Fig. 1) [31,34]. Reciprocally,  
 expression of a constitutively active form of the Notch receptor in  
 the intestinal epithelium dramatically impairs cell differentiation  
 and increases the proportion of dividing cells, that extend outside  
 of the crypt proliferative compartment, and are found all along the  
 vertical axis of the villi [32]. These studies revealed two essential  
 functions of Notch in gut homeostasis: on one hand, Notch is  
 required to promote stem cell self-renewal in the intestinal crypts,



Adapted from J. Lewis, 2006

**Fig. 2 – Schematic view of intestinal homeostasis in the fly and the mouse. In the fly, multipotent stem cells express both the Notch receptor and the ligand Delta. Notch is active in the enteroblast progenitor. During the differentiation process, low Notch activity gives rise to the secretory lineage (enteroendocrine cells) while high Notch activity leads to the absorptive lineage. In the mouse, the Notch receptor is probably active in stem cells and progenitors, while Paneth cells appear to express the ligand Delta. During cell fate acquisition, Notch signaling blocks the secretory lineage, while it is permissive for enterocyte differentiation.**

225 and on the other Notch signals are dictating the differentiation fate  
226 of cells at commitment by a lateral inhibition mechanism [35].

227 The role of Notch in promoting intestinal proliferation requires  
228 Wnt signals, since only cells with intact Wnt signaling are  
229 “competent” to respond to the Notch-dependent mitogenic  
230 stimulus. On the contrary, Notch controls cell differentiation  
231 independently of Wnt signals [36] and through the transcriptional  
232 activation of Hes1 that in turns represses the secretory cell  
233 determinant Math1. The bHLH transcription factor Math1 is  
234 absolutely required to specify intestinal secretory cells [28] and  
235 indeed mediates the function of Notch on cell fate specification in  
236 the crypt. Genetic evidence that Math1 functions downstream of  
237 Notch signaling in allocating intestinal epithelial lineages comes  
238 from the study of conditional compound mutant mice that lack  
239 intestinal expression of both RBPJ $\kappa$  and Math1. The combined  
240 genetic loss of Math1 and RBPJ $\kappa$  completely rescues the intestinal  
241 phenotypes associated with loss of RBPJ $\kappa$  and establishes that  
242 Math1 is epistatic to Notch signaling in secretory cell specification  
243 [34]. Importantly, Math1 activation also leads to increased  
244 expression of the Notch ligand Delta-like 1, possibly mediating a  
245 negative regulatory loop blocking Notch receptor expression and  
246 activation in the same cell, thus allowing the Math1-expressing  
247 cell to acquire a secretory fate [37].

248 Interestingly,  $\gamma$ -secretase inhibitors of Notch activation can  
249 both reduce proliferation and induce secretory cells differentiation;

250 however, the simultaneous targeting of Notch1 and Notch2 with an  
251 siRNA approach is sufficient to induce markers of goblet cell  
252 differentiation, but fails to alter proliferation in colon cancer cells  
253 [38]. These results may be related to our findings that cells respond  
254 to a Notch-dependent mitogenic stimulus only when the Wnt  
255 cascade is intact, while the effect of Notch on cell differentiation is  
256 independent of Wnt [36]. Thus, a lack of effect on proliferation by  
257 siRNA reduction of Notch1 and Notch2, but modulation of  
258 differentiation, could be due to altered Wnt signaling in colon  
259 cancer cells. Similar results were reported by Rodilla et al. [39] who  
260 showed that expression of the active Notch in cells depleted for  
261 Tcf4 are able to regulate differentiation but not proliferation.

262 Two of the four mammalian Notch receptor paralogues have  
263 been found to be involved in mediating a gatekeeper function in  
264 the undifferentiated cells of the crypt: Notch1 and Notch2.  
265 Through inducible and tissue-specific loss-of-function approaches,  
266 Notch1 and Notch2 have been found to have redundant functions  
267 in the intestine [40]. On the other hand, Wu et al. recently reported  
268 that the specific inhibition of Notch1, but not Notch2, by  
269 antagonistic antibodies is sufficient to reveal a partial Notch  
270 block phenotype in the intestinal crypt, marked by a decrease of  
271 proliferative cells and an increase of secretory goblet cells [41]. The  
272 existing evidence therefore suggests an overlapping, but not  
273 completely redundant function of the two Notch receptors in the  
274 intestinal epithelium.



275 Activation of Notch signaling in intestinal stem cells has  
276 recently been described using a Notch1 activation-dependent  
277 knock-in mouse line, NIP1::CreERT2 [42]. In this report, stem cell  
278 labeling has been indirectly assessed, by tracing the progeny of  
279 cells in which Notch activation had occurred. Importantly, the  
280 authors show that tissue-specific deletion of the two Notch ligands  
281 Delta-like 1 and Delta-like 4, as well as of the major Notch effector  
282 RBPJ $\kappa$ , leads to loss of stem cell markers (Lgr5, Olfm4, Ascl2),  
283 strongly suggesting an essential function for Notch signaling in  
284 stem cell maintenance. Further genetic evidence for Notch  
285 activation in crypt stem cells comes from lineage tracing data  
286 showing that the Notch target Hes1 labels multipotent intestinal  
287 stem cells [43].

288 Notwithstanding previous reports suggesting that intestinal  
289 stem cells are completely autonomous and self-organizing units  
290 [44], the existence of a cellular niche for crypt stem cells has been  
291 recently demonstrated [45]. Paneth cells, representing a special-  
292 ized type of secretory cells residing at the bottom of crypts in close  
293 contact with stem cells, have been indeed shown to be essential for  
294 stem cell survival, since *in vivo* genetic ablation of this cell type  
295 results in stem cell loss. Interestingly, Paneth cells express several  
296 ligands for major signaling pathways, such as EGF, TGF- $\alpha$ , Wnt3  
297 and the Notch ligand Delta-like 4. The above mentioned  
298 disappearance of stem cells upon genetic deletion of Delta-like 1  
299 and Delta-like 4, therefore, could be explained by the loss of niche  
300 support due to impairment of Paneth cell specification and  
301 function in this mutant background.

302 While the identity of the Notch-expressing cells in the intestine  
303 is still unclear due to the lack of reliable antibodies, the expression  
304 pattern of Hes1 in the crypts tightly correlates with the expression  
305 of the RNA-binding protein Musashi-1 (Msi-1) [46], a marker of  
306 neural and intestinal stem cells. In the embryonic central nervous  
307 system, Msi-1 appears to be able of activating Notch signaling  
308 through repression of translation of the mRNA of the Notch  
309 inhibitor m-Numb [47,48]. However, it is currently unknown if  
310 Msi-1 can activate the Notch pathway in the intestinal crypts.  
311 Importantly, in the mouse intestine, both Msi-1 and Hes1 are  
312 expressed in cells just above the Paneth cells, as well as in the crypt  
313 base columnar cells intercalated between Paneth cells at the base  
314 of the crypt [46]. Both these types of cells have been shown to  
315 represent intestinal stem cells responsible for the renewal of the  
316 gut epithelium that occurs throughout adulthood [49].

317 There exists a striking similarity between the fly, the fish and  
318 the mouse in the conserved role of Notch signaling in dictating  
319 intestinal cell fate specification. One apparent difference, however,  
320 is the impact that Notch signals have on the self-renewing  
321 properties of intestinal stem cells in *Drosophila* and in the  
322 mouse crypt. While the loss of Notch signaling in *Drosophila*  
323 expands the number of stem cell-like cells, it depletes the stem cell  
324 compartment in the mouse. Conversely, Notch activation in the  
325 mouse intestine increases the numbers of proliferating stem cells  
326 and progenitors, while preventing their terminal differentiation;  
327 Notch activation in the fly intestinal stem cells forces their  
328 differentiation as enterocytes. At a closer examination, however,  
329 what Notch signaling does in both systems is to promote the fate of  
330 early progenitors (a transit-amplifying compartment in the mouse  
331 crypt and the enteroblasts in flies). The major difference is that the  
332 enteroblasts do not divide, while mouse progenitors do, and  
333 therefore the nature of the Notch transcriptional program likely  
334 differs in control of cell cycle regulation.

## Notch signals in intestinal tumors

336

In spite of the paucity of current data directly implicating Notch  
337 signaling in colorectal cancer, several lines of evidence support the  
338 hypothesis that Notch signals have a positive impact on intestinal  
339 tumorigenesis. 340

A connection between Notch and intestinal tumors arises from  
341 studies showing that Hes-1, a signature of Notch signal activation  
342 whose expression is normally restricted to the crypt proliferative  
343 compartment, is also uniformly observed in adenomas formed in  
344 the intestine of mice carrying *Apc* mutations that lead to  
345 constitutive activation of the Wnt pathway [31,36]. Indeed there  
346 is a strong symmetry between crypts and intestinal neoplasia and  
347 these observations imply that Notch signaling is active not only in  
348 crypt progenitors, but also in some tumor cells. In addition, Notch  
349 inhibition has been reported to significantly reduce tumor size and  
350 incidence in adenomas that spontaneously occur in Multiple  
351 intestinal neoplasia (Min) mice [31,39,50], suggesting that the  
352 maintenance of the proliferative potential of intestinal adenoma  
353 cells depends on Notch activity. 354

These observations strongly suggest an important role for  
355 Notch signaling in regulating stem cell self-renewal during  
356 normal homeostasis and imply the value of exploring if Notch  
357 signals can contribute to the maintenance of cancer stem cells in  
358 this organ. 359

In other tissues, such as the hematopoietic system, it has been  
360 clearly established that the primary events in tumorigenesis are  
361 linked to stem cell transformation [51,52]. The existence of cancer  
362 stem cells in human colorectal tumors has recently been shown  
363 [53,54] and they represent a rare population of undifferentiated  
364 cells, responsible for tumor formation and for sustaining tumor  
365 growth. This subset of cells, referred to as cancer initiating stem  
366 cells (CISC), share many properties with physiological stem cells,  
367 but it is still unclear whether they originate from normal stem cells  
368 or by dedifferentiation of somatic tumor cells to stem-like cells. 369

The analogy between physiological stem cells and CISC is  
370 reflected in the intestine by the strong expression of both Msi-1  
371 and Hes-1 in intestinal tumors of *Apc* mutant mice as well as in  
372 human colorectal tumors [36,55,56]. Indeed, siRNA-mediated  
373 knockdown of Msi-1 in colon adenocarcinoma xenografts induces  
374 tumor growth arrest. Inhibition of Msi-1 in these xenografts  
375 results in decreased cancer cell proliferation, increased apoptosis  
376 and down-regulation of activated Notch-1 [55]. In addition, both  
377 pharmacological and siRNA-mediated Notch inhibition in human  
378 colon cancer initiating cells has shown the critical requirement for  
379 Notch signals in maintaining self-renewal and preventing secre-  
380 tory lineage differentiation genes [57]. Taken together, these  
381 observations suggest that elevated Notch signaling may contribute  
382 to the initiation of colorectal cancer, by controlling the mainte-  
383 nance of the undifferentiated state of intestinal neoplastic cells. 384

While more than 50% of T cell Acute Lymphoblastic Leukemia  
385 (T-ALL) patients exhibit activating Notch receptor mutations [58],  
386 no one has yet reported genetic mutations in Notch receptors,  
387 ligands or in the effector RBPJ in colorectal cancer. Our findings in  
388 mouse and human tumor specimens show aberrant Notch  
389 activation almost exclusively in early stages of benign intestinal  
390 adenomas, suggesting that Notch may not play a role during  
391 carcinoma progression [36]. We therefore propose that aberrant  
392 Notch activation in a specific subset of cells can provide a 393

394 developmental context that is favorable for the accumulation of  
395 oncogenic mutations that will trigger intestinal tumorigenesis.

### 396 Conclusive remarks

398 The analysis of Notch function in the same organ of different  
399 species has proven extremely valuable as it allows exploiting the  
400 specific advantages of each model system to highlight both  
401 conserved and divergent functions across species barriers. The  
402 results obtained to date comparing *Drosophila*, Zebrafish and  
403 mouse suggest that the essential role of Notch signaling in the  
404 control of intestinal homeostasis reflects a fundamental mechanism.

405 The genetic events that underlie the initiation and progression  
406 of colorectal tumors provide a remarkable example of the multi-  
407 step process at the origin of human cancers formalized in classic  
408 papers from the group of B. Vogelstein [59,60].

409 Accordingly, the sequential nature of colorectal tumor devel-  
410 opment is directly linked to loss or gain of function mutations  
411 occurring in well-known tumor suppressor genes or oncogenes.  
412 Yet so far no mutations of the Notch gene itself, or of the other  
413 major components of the Notch pathway, have been reported.  
414 Future studies should aim at identifying the molecular mechanisms  
415 triggering Notch activation in the gut. One may anticipate that  
416 various acute or chronic physio-pathological conditions may drive  
417 Notch activation (as in inflammatory bowel or infectious diseases).

418 The role of Notch signaling in colon cancer implies a distinct  
419 mode of action from that of conventional oncogenes. Specifically, its  
420 high context specificity and the frequently contradictory action in  
421 different tissues suggest that it does not behave as an oncogene *per se*.  
422 It is more likely that it exerts its oncogenic potential by facilitating  
423 the expansion or depletion of certain cell subpopulations in a given  
424 tissue with different susceptibility to tumorigenesis. A transient  
425 increase of cell proliferation in the crypt would indeed amplify a cell  
426 population that could be a dangerous target for mutations (*i.e.* stem  
427 cells or early progenitors). In summary, despite the fundamental role  
428 that Notch signaling plays in maintaining a proliferating cell  
429 phenotype in the normal intestinal epithelium, and despite its role  
430 in tumorigenesis, it is likely that effective therapeutic targeting will  
431 require multiple strategies based on the mechanisms underlying  
432 Notch deregulation in different subsets of colorectal tumors.

433 A generality that can be drawn regarding the action of Notch  
434 signals in development is that modulation of the Notch pathway in  
435 cells that are not terminally differentiated provides them with the  
436 plasticity to change developmental fate. Based on this rationale, it  
437 has been suggested that modulation of Notch signals in tumor cells  
438 may force cell fate changes that, depending on the context, may have  
439 therapeutic value, as they will possibly force tumor cells into a less  
440 malignant state. Future studies are expected to clarify these issues  
441 and elucidate the precise mode of Notch action in tumorigenesis.

### 442 REFERENCES

- 443 [1] S. Artavanis-Tsakonas, M.D. Rand, R.J. Lake, Notch signaling: cell  
444 fate control and signal integration in development, *Science* 284  
445 (1999) 770–776.  
446 [2] G.D. Hurlbut, M.W. Kankel, R.J. Lake, S. Artavanis-Tsakonas,  
447 Crossing paths with Notch in the hyper-network, *Curr. Opin. Cell*  
448 *Biol.* 19 (2007) 166–175.  
449

- [3] M.P. Bulman, K. Kusumi, T.M. Frayling, C. McKeown, C. Garrett, 450  
E.S. Lander, R. Krumlauf, A.T. Hattersley, S. Ellard, P.D. Turnpenny, 451  
Mutations in the human delta homologue, *DLL3*, cause axial 452  
skeletal defects in spondylocostal dysostosis, *Nat. Genet.* 24 453  
(2000) 438–441. 454  
[4] V. Garg, A.N. Muth, J.F. Ransom, M.K. Schluterman, R. Barnes, I.N. 455  
King, P.D. Grossfeld, D. Srivastava, Mutations in *NOTCH1* cause 456  
aortic valve disease, *Nature* 437 (2005) 270–274. 457  
[5] L. Li, I.D. Krantz, Y. Deng, A. Genin, A.B. Banta, C.C. Collins, M. Qi, 458  
B.J. Trask, W.L. Kuo, J. Cochran, T. Costa, M.E. Pierpont, E.B. Rand, 459  
D.A. Piccoli, L. Hood, N.B. Spinner, Alagille syndrome is caused by 460  
mutations in human *Jagged1*, which encodes a ligand for Notch1, 461  
*Nat. Genet.* 16 (1997) 243–251. 462  
[6] A. Louvi, J.F. Arboleda-Velasquez, S. Artavanis-Tsakonas, *CADA-* 463  
*SIL*: a critical look at a Notch disease, *Dev. Neurosci.* 28 (2006) 464  
5–12. 465  
[7] M.A. Simpson, M.D. Irving, E. Asilmaz, M.J. Gray, D. Dafou, F.V. 466  
Elmslie, S. Mansour, S.E. Holder, C.E. Brain, B.K. Burton, K.H. Kim, 467  
R.M. Pauli, S. Aftimos, H. Stewart, C.A. Kim, M. Holder-Espinasse, 468  
S.P. Robertson, W.M. Drake, R.C. Trembath, Mutations in *NOTCH2* 469  
cause Hajdu-Cheney syndrome, a disorder of severe and 470  
progressive bone loss, *Nat. Genet.* 43 (2011) 303–305. 471  
[8] L.W. Ellisen, J. Bird, D.C. West, A.L. Soreng, T.C. Reynolds, S.D. 472  
Smith, J. Sklar, *TAN-1*, the human homolog of the *Drosophila* 473  
notch gene, is broken by chromosomal translocations in T 474  
lymphoblastic neoplasms, *Cell* 66 (1991) 649–661. 475  
[9] D. Bellavia, A.F. Campese, E. Alesse, A. Vacca, M.P. Felli, A. Balestri, 476  
A. Stoppacciaro, C. Tiveron, L. Tatangelo, M. Giovarelli, C. Gaetano, 477  
L. Ruco, E.S. Hoffman, A.C. Hayday, U. Lendahl, L. Frati, A. Gulino, I. 478  
Screpanti, Constitutive activation of NF-kappaB and T-cell 479  
leukemia/lymphoma in *Notch3* transgenic mice, *EMBO J.* 19 480  
(2000) 3337–3348. 481  
[10] A. Dievert, N. Beaulieu, P. Jolicoeur, Involvement of Notch1 in the 482  
development of mouse mammary tumors, *Oncogene* 18 (1999) 483  
5973–5981. 484  
[11] D. Gallahan, C. Jhappan, G. Robinson, L. Hennighausen, R. Sharp, E. 485  
Kordon, R. Callahan, G. Merlino, G.H. Smith, Expression of a 486  
truncated *Int3* gene in developing secretory mammary epithelium 487  
specifically retards lobular differentiation resulting in 488  
tumorigenesis, *Cancer Res.* 56 (1996) 1775–1785. 489  
[12] R. Hubmann, J.D. Schwarzmeier, M. Shehata, M. Hilgarth, M. 490  
Duechler, M. Dettke, R. Berger, Notch2 is involved in the 491  
overexpression of CD23 in B-cell chronic lymphocytic leukemia, 492  
*Blood* 99 (2002) 3742–3747. 493  
[13] C. Jhappan, D. Gallahan, C. Stahle, E. Chu, G.H. Smith, G. Merlino, R. 494  
Callahan, Expression of an activated Notch-related *int-3* 495  
transgene interferes with cell differentiation and induces 496  
neoplastic transformation in mammary and salivary glands, 497  
*Genes Dev.* 6 (1992) 345–355. 498  
[14] C.A. Micchelli, N. Perrimon, Evidence that stem cells reside in the 499  
adult *Drosophila* midgut epithelium, *Nature* 439 (2006) 475–479. 500  
[15] B. Ohlstein, A. Spradling, The adult *Drosophila* posterior midgut is 501  
maintained by pluripotent stem cells, *Nature* 439 (2006) 502  
470–474. 503  
[16] N. Buchon, N.A. Broderick, M. Poidevin, S. Pradervand, B. Lemaitre, 504  
*Drosophila* intestinal response to bacterial infection: activation of 505  
host defense and stem cell proliferation, *Cell Host Microbe* 5 506  
(2009) 200–211. 507  
[17] H. Jiang, M.O. Grenley, M.J. Bravo, R.Z. Blumhagen, B.A. Edgar, 508  
*EGFR/Ras/MAPK* signaling mediates adult midgut epithelial 509  
homeostasis and regeneration in *Drosophila*, *Cell Stem Cell* 510  
8 (2011) 84–95. 511  
[18] H. Jiang, P.H. Patel, A. Kohlmaier, M.O. Grenley, D.G. McEwen, B.A. 512  
Edgar, Cytokine/Jak/Stat signaling mediates regeneration and 513  
homeostasis in the *Drosophila* midgut, *Cell* 137 (2009) 514  
1343–1355. 515  
[19] G. Lin, N. Xu, R. Xi, Paracrine Wingless signalling controls 516  
self-renewal of *Drosophila* intestinal stem cells, *Nature* 455 517  
(2008) 1119–1123. 518

- 519 [20] B. Ohlstein, A. Spradling, Multipotent *Drosophila* intestinal stem  
520 cells specify daughter cell fates by differential notch signaling,  
521 *Science* 315 (2007) 988–992.
- 522 [21] A.J. Bardin, C.N. Perdigoto, T.D. Southall, A.H. Brand, F. Schweisguth,  
523 Transcriptional control of stem cell maintenance in the *Drosophila*  
524 intestine, *Development* 137 (2010) 705–714.
- 525 [22] M. Buszczak, S. Paterno, A.C. Spradling, *Drosophila* stem cells  
526 share a common requirement for the histone H2B ubiquitin  
527 protease scrawny, *Science* 323 (2009) 248–251.
- 528 [23] P. Heitzler, M. Bourouis, L. Ruel, C. Carteret, P. Simpson, Genes of  
529 the Enhancer of split and achaete-scute complexes are required  
530 for a regulatory loop between Notch and Delta during lateral  
531 signalling in *Drosophila*, *Development* 122 (1996) 161–171.
- 532 [24] M. Kunsch, M. Haenlin, J.A. Campos-Ortega, Lateral inhibition  
533 mediated by the *Drosophila* neurogenic gene delta is enhanced by  
534 proneural proteins, *Proc. Natl. Acad. Sci. U. S. A.* 91 (1994)  
535 10139–10143.
- 536 [25] L.G. van der Flier, M.E. van Gijn, P. Hatzis, P. Kujala, A. Haegebarth,  
537 D.E. Stange, H. Begthel, M. van den Born, V. Guryev, I. Oving, J.H.  
538 van Es, N. Barker, P.J. Peters, M. van de Wetering, H. Clevers,  
539 Transcription factor achaete scute-like 2 controls intestinal stem  
540 cell fate, *Cell* 136 (2009) 903–912.
- 541 [26] M. Jenny, C. Uhl, C. Roche, I. Duluc, V. Guillermin, F. Guillemot, J.  
542 Jensen, M. Kedinger, G. Gradwohl, Neurogenin3 is differentially  
543 required for endocrine cell fate specification in the intestinal and  
544 gastric epithelium, *EMBO J.* 21 (2002) 6338–6347.
- 545 [27] C.S. Lee, N. Perreault, J.E. Brestelli, K.H. Kaestner, Neurogenin 3 is  
546 essential for the proper specification of gastric enteroendocrine  
547 cells and the maintenance of gastric epithelial cell identity, *Genes*  
548 *Dev.* 16 (2002) 1488–1497.
- 549 [28] Q. Yang, N.A. Bermingham, M.J. Finegold, H.Y. Zoghbi, Requirement  
550 of Math1 for secretory cell lineage commitment in the mouse  
551 intestine, *Science* 294 (2001) 2155–2158.
- 552 [29] C. Crosnier, N. Vargesson, S. Gschmeissner, L. Ariza-McNaughton, A.  
553 Morrison, J. Lewis, Delta-Notch signalling controls commitment to a  
554 secretory fate in the zebrafish intestine, *Development* 132 (2005)  
555 1093–1104.
- 556 [30] J. Yang, C.Y. Chan, B. Jiang, X. Yu, G.Z. Zhu, Y. Chen, J. Barnard, W.  
557 Mei, hnRNP I inhibits Notch signaling and regulates intestinal  
558 epithelial homeostasis in the zebrafish, *PLoS Genet.* 5 (2009)  
559 e1000363.
- 560 [31] J.H. van Es, M.E. van Gijn, O. Riccio, M. van den Born, M. Vooijs, H.  
561 Begthel, M. Cozijnsen, S. Robine, D.J. Winton, F. Radtke, H. Clevers,  
562 Notch/gamma-secretase inhibition turns proliferative cells in  
563 intestinal crypts and adenomas into goblet cells, *Nature* 435  
564 (2005) 959–963.
- 565 [32] S. Fre, M. Huyghe, P. Mourikis, S. Robine, D. Louvard, S.  
566 Artavanis-Tsakonas, Notch signals control the fate of immature  
567 progenitor cells in the intestine, *Nature* 435 (2005) 964–968.
- 568 [33] S. Jarriault, C. Brou, F. Logeat, E.H. Schroeter, R. Kopan, A. Israel,  
569 Signalling downstream of activated mammalian Notch [see  
570 comments], *Nature* 377 (1995) 355–358.
- 571 [34] T.H. Kim, R.A. Shivdasani, Genetic evidence that intestinal notch  
572 functions vary regionally and operate through a common  
573 mechanism of math1 repression, *J. Biol. Chem.* (2011).
- 574 [35] C. Crosnier, D. Stamatakis, J. Lewis, Organizing cell renewal in the  
575 intestine: stem cells, signals and combinatorial control, *Nat. Rev.*  
576 *Genet.* 7 (2006) 349–359.
- 577 [36] S. Fre, S.K. Pallavi, M. Huyghe, M. Lae, K.P. Janssen, S. Robine, S.  
578 Artavanis-Tsakonas, D. Louvard, Notch and Wnt signals  
579 cooperatively control cell proliferation and tumorigenesis in the  
580 intestine, *Proc. Natl. Acad. Sci. U. S. A.* 106 (2009) 6309–6314.
- 581 [37] A. Kazanjian, T. Noah, D. Brown, J. Burkart, N.F. Shroyer, Atonal  
582 homolog 1 is required for growth and differentiation effects of  
583 notch/gamma-secretase inhibitors on normal and cancerous  
584 intestinal epithelial cells, *Gastroenterology* 139 (2010) 918–928  
585 e911–916.
- 586 [38] S. Guilmeau, M. Flandez, J.M. Mariadason, L.H. Augenlicht,  
587 Heterogeneity of Jagged1 expression in human and mouse  
intestinal tumors: implications for targeting Notch signaling, *588*  
*Oncogene* 29 (2009) 992–1002. 589
- [39] V. Rodilla, A. Villanueva, A. Obrador-Hevia, A. Robert-Moreno, V.  
590 Fernandez-Majada, A. Grilli, N. Lopez-Bigas, N. Bellora, M.M. Alba,  
591 F. Torres, M. Dunach, X. Sanjuan, S. Gonzalez, T. Gridley, G.  
592 Capella, A. Bigas, L. Espinosa, Jagged1 is the pathological link  
593 between Wnt and Notch pathways in colorectal cancer, *Proc. Natl.*  
594 *Acad. Sci. U. S. A.* 106 (2009) 6315–6320. 595
- [40] O. Riccio, M.E. van Gijn, A.C. Bezdek, L. Pellegrinet, J.H. van  
596 Es, U. Zimmer-Strobl, L.J. Strobl, T. Honjo, H. Clevers, F.  
597 Radtke, Loss of intestinal crypt progenitor cells owing to  
598 inactivation of both Notch1 and Notch2 is accompanied by  
599 derepression of CDK inhibitors p27Kip1 and p57Kip2, *EMBO*  
600 *Rep.* 9 (2008) 377–383. 601
- [41] Y. Wu, C. Cain-Hom, L. Choy, T.J. Hagenbeek, G.P. de Leon, Y. Chen,  
602 D. Finkle, R. Venook, X. Wu, J. Ridgway, D. Schahin-Reed, G.J. Dow,  
603 A. Shelton, S. Stawicki, R.J. Watts, J. Zhang, R. Choy, P. Howard, L.  
604 Kadyk, M. Yan, J. Zha, C.A. Callahan, S.G. Hymowitz, C.W. Siebel,  
605 Therapeutic antibody targeting of individual Notch receptors,  
606 *Nature* 464 (2010) 1052–1057. 607
- [42] L. Pellegrinet, V. Rodilla, Z. Liu, S. Chen, U. Koch, L. Espinosa, K.H.  
608 Kaestner, R. Kopan, J. Lewis, F. Radtke, Dll1- and Dll4-mediated  
609 Notch signaling is required for homeostasis of intestinal stem  
610 cells, *Gastroenterology* (2011). 611
- [43] D. Kopinke, M. Brailsford, J.E. Shea, R. Leavitt, C.L. Scaife, L.C.  
612 Murtaugh, Lineage tracing reveals the dynamic contribution of  
613 Hes1+ cells to the developing and adult pancreas, *Development*  
614 138 (2011) 431–441. 615
- [44] T. Sato, R.G. Vries, H.J. Snippert, M. van de Wetering, N. Barker,  
616 D.E. Stange, J.H. van Es, A. Abo, P. Kujala, P.J. Peters, H. Clevers,  
617 Single Lgr5 stem cells build crypt-villus structures in vitro  
618 without a mesenchymal niche, *Nature* 459 (2009) 262–265. 619
- [45] T. Sato, J.H. van Es, H.J. Snippert, D.E. Stange, R.G. Vries, M. van den  
620 Born, N. Barker, N.F. Shroyer, M. van de Wetering, H. Clevers,  
621 Paneth cells constitute the niche for Lgr5 stem cells in intestinal  
622 crypts, *Nature* 469 (2011) 415–418. 623
- [46] T. Kayahara, M. Sawada, S. Takaishi, H. Fukui, H. Seno, H.  
624 Fukuzawa, K. Suzuki, H. Hiai, R. Kageyama, H. Okano, T. Chiba,  
625 Candidate markers for stem and early progenitor cells, Musashi-1  
626 and Hes1, are expressed in crypt base columnar cells of mouse  
627 small intestine, *FEBS Lett.* 535 (2003) 131–135. 628
- [47] H. Okano, T. Imai, M. Okabe, Musashi: a translational regulator of  
629 cell fate, *J. Cell Sci.* 115 (2002) 1355–1359. 630
- [48] H. Okano, H. Kawahara, M. Toriya, K. Nakao, S. Shibata, T. Imai,  
631 Function of RNA-binding protein Musashi-1 in stem cells, *Exp.*  
632 *Cell Res.* 306 (2005) 349–356. 633
- [49] N. Barker, J.H. van Es, J. Kuipers, P. Kujala, M. van den Born, M.  
634 Cozijnsen, A. Haegebarth, J. Korving, H. Begthel, P.J. Peters, H.  
635 Clevers, Identification of stem cells in small intestine and colon by  
636 marker gene Lgr5, *Nature* 449 (2007) 1003–1007. 637
- [50] A.M. Ghaleb, G. Aggarwal, A.B. Bialkowska, M.O. Nandan, V.W.  
638 Yang, Notch inhibits expression of the Kruppel-like factor 4 tumor  
639 suppressor in the intestinal epithelium, *Mol. Cancer Res.* 6 (2008)  
640 1920–1927. 641
- [51] E. Passegue, C.H. Jamieson, L.E. Ailles, I.L. Weissman, Normal and  
642 leukemic hematopoiesis: are leukemias a stem cell disorder or a  
643 reacquisition of stem cell characteristics? *Proc. Natl. Acad. Sci. U.*  
644 *S. A.* 100 (Suppl 1) (2003) 11842–11849. 645
- [52] D. Bonnet, Cancer stem cells: lessons from leukaemia, *Cell Prolif.*  
646 38 (2005) 357–361. 647
- [53] C.A. O'Brien, A. Pollett, S. Gallinger, J.E. Dick, A human colon cancer  
648 cell capable of initiating tumour growth in immunodeficient mice,  
649 *Nature* 445 (2007) 106–110. 650
- [54] L. Ricci-Vitiani, D.G. Lombardi, E. Pilozzi, M. Biffoni, M.  
651 Todaro, C. Peschle, R. De Maria, Identification and expansion  
652 of human colon-cancer-initiating cells, *Nature* 445 (2007)  
653 111–115. 654
- [55] S.M. Sureban, R. May, R.J. George, B.K. Dieckgraefe, H.L. McLeod, S.  
655 Ramalingam, K.S. Bishnupuri, G. Natarajan, S. Anant, C.W. 656

- 657 Houchen, Knockdown of RNA binding protein musashi-1 leads to  
658 tumor regression in vivo, *Gastroenterology* 134 (2008)  
659 1448–1458.
- 660 [56] L.M. Veenendaal, O. Kranenburg, N. Smakman, A. Klomp, I.H. Borel  
661 Rinke, P.J. van Diest, Differential Notch and TGFbeta signaling in  
662 primary colorectal tumors and their corresponding metastases,  
663 *Cell. Oncol.* 30 (2008) 1–11.
- 664 [57] S.S. Sikandar, K.T. Pate, S. Anderson, D. Dizon, R.A. Edwards, M.L.  
665 Waterman, S.M. Lipkin, NOTCH signaling is required for formation  
666 and self-renewal of tumor-initiating cells and for repression of  
677 secretory cell differentiation in colon cancer, *Cancer Res.* 70  
(2010) 1469–1478. 667
- [58] A.P. Weng, A.A. Ferrando, W. Lee, J.P.t. Morris, L.B. Silverman, C.  
Sanchez-Irizarry, S.C. Blacklow, A.T. Look, J.C. Aster, Activating  
mutations of NOTCH1 in human T cell acute lymphoblastic  
leukemia, *Science* 306 (2004) 269–271. 670
- [59] K.W. Kinzler, B. Vogelstein, Landscaping the cancer terrain,  
*Science* 280 (1998) 1036–1037. 673
- [60] B. Vogelstein, K.W. Kinzler, The multistep nature of cancer, *Trends*  
*Genet.* 9 (1993) 138–141. 675

UNCORRECTED PROOF